301 related articles for article (PubMed ID: 17904211)
1. Aspirin use for the primary prevention of coronary heart disease: a population-based study in Switzerland.
Rodondi N; Cornuz J; Marques-Vidal P; Butler J; Hayoz D; Pécoud A; Paccaud F; Waeber G; Vollenweider P
Prev Med; 2008 Feb; 46(2):137-44. PubMed ID: 17904211
[TBL] [Abstract][Full Text] [Related]
2. Aspirin use for the primary prevention of coronary heart disease in older adults.
Rodondi N; Vittinghoff E; Cornuz J; Butler J; Ding J; Satterfield S; Newman AB; Harris TB; Hulley SB; Bauer DC;
Am J Med; 2005 Nov; 118(11):1288. PubMed ID: 16271917
[TBL] [Abstract][Full Text] [Related]
3. [The role of aspirin in the primary prevention of cardiovascular disease].
Rodondi N; Cornuz J
Rev Med Suisse; 2006 Mar; 2(56):646-51. PubMed ID: 16597054
[TBL] [Abstract][Full Text] [Related]
4. Primary prevention of coronary heart disease in the elderly.
Dornbrook-Lavender KA; Pieper JA; Roth MT
Ann Pharmacother; 2003 Nov; 37(11):1654-63. PubMed ID: 14565805
[TBL] [Abstract][Full Text] [Related]
5. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.
Morimoto T; Fukui T; Lee TH; Matsui K
Am J Med; 2004 Oct; 117(7):459-68. PubMed ID: 15464702
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular risk estimation and eligibility for statins in primary prevention comparing different strategies.
Nanchen D; Chiolero A; Cornuz J; Marques-Vidal PM; Firmann M; Mooser V; Paccaud F; Waeber G; Vollenweider P; Rodondi N
Am J Cardiol; 2009 Apr; 103(8):1089-95. PubMed ID: 19361595
[TBL] [Abstract][Full Text] [Related]
7. Increasing aspirin use among persons at risk for cardiovascular events in Oklahoma.
Mallonee S; Daniels CG; Mold JW; Cline TL
J Okla State Med Assoc; 2010 Jul; 103(7):254-60. PubMed ID: 20821923
[TBL] [Abstract][Full Text] [Related]
8. [Primary prevention of coronary heart disease with aspirin].
Kübler W
Z Kardiol; 2004; 93 Suppl 2():II33-6. PubMed ID: 15021994
[TBL] [Abstract][Full Text] [Related]
9. Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation.
Annemans L; Lamotte M; Kubin M; Evers T; Verheugt FW
Int J Clin Pract; 2006 Sep; 60(9):1129-37. PubMed ID: 16939558
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin.
Bartolucci AA; Howard G
Am J Cardiol; 2006 Sep; 98(6):746-50. PubMed ID: 16950176
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
Greving JP; Buskens E; Koffijberg H; Algra A
Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010
[TBL] [Abstract][Full Text] [Related]
12. Use of antiplatelet therapy in a diabetic outpatient service of a large urban public hospital.
Bruno A; Grassi G; Dani F; Degiovanni M; Maghenzani G; Pagano G
Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):42-6. PubMed ID: 15871850
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacologic interventions in primary prevention: lipid lowering drugs, aspirin, antiobesity drugs, and antihypertensive agents].
Auer J; Berent R; Weber T; Porodko M; Mayr H; Maurer E; Eber B
Wien Med Wochenschr; 2001; 151(1-2):13-7. PubMed ID: 11234591
[TBL] [Abstract][Full Text] [Related]
14. Aspirin for primary prevention of cardiovascular events in people with diabetes.
Pignone M; Alberts MJ; Colwell JA; Cushman M; Inzucchi SE; Mukherjee D; Rosenson RS; Williams CD; Wilson PW; Kirkman MS; ; ;
J Am Coll Cardiol; 2010 Jun; 55(25):2878-86. PubMed ID: 20579547
[No Abstract] [Full Text] [Related]
15. Low-dose aspirin in the primary prevention of cardiovascular disease: how to balance the benefits and the risks.
De Caterina R
Ital Heart J; 2003 Apr; 4(4):228-31. PubMed ID: 12784774
[TBL] [Abstract][Full Text] [Related]
16. The association between socioeconomic status of high-risk patients with coronary heart disease and the treatment rates of evidence-based medicine for coronary heart disease secondary prevention in China: Results from the Bridging the Gap on CHD Secondary Prevention in China (BRIG) Project.
Niu S; Zhao D; Zhu J; Liu J; Liu Q; Liu J; Wang W; Smith SC;
Am Heart J; 2009 Apr; 157(4):709-15.e1. PubMed ID: 19332200
[TBL] [Abstract][Full Text] [Related]
17. The influence of obesity and consequent insulin resistance on coronary risk factors in medically treated patients with coronary disease.
Ades PA; Savage PD; Toth MJ; Schneider DJ; Audelin MC; Bunn JY; Ludlow M
Int J Obes (Lond); 2008 Jun; 32(6):967-74. PubMed ID: 18268512
[TBL] [Abstract][Full Text] [Related]
18. [Primary prevention of cardiovascular diseases with acetylsalicylic acid].
Waltering A; Hemkens L; Florack C
Dtsch Med Wochenschr; 2005 Dec; 130(49):2847-52. PubMed ID: 16317615
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention.
Saini SD; Schoenfeld P; Fendrick AM; Scheiman J
Arch Intern Med; 2008 Aug; 168(15):1684-90; discussion 1691. PubMed ID: 18695083
[TBL] [Abstract][Full Text] [Related]
20. Aspirin and heart disease.
Nurse Pract; 1996 Nov; 21(11):111-2. PubMed ID: 8933540
[No Abstract] [Full Text] [Related]
[Next] [New Search]
